What are SNY's recent SEC filings?
Sanofi reported Q3 2026 results with double-digit growth in sales and business EPS, and upgraded its full-year 2026 guidance.
View full filing details →Sanofi announced it broke ground on a new state-of-the-art insulin manufacturing facility in Germany, as detailed in a press release dated October 19, 2026.
View full filing details →Sanofi filed an amended Schedule 13G indicating a passive institutional ownership position. The filing text provided contains only EDGAR directory listing metadata and no substantive ownership details.
View full filing details →Sanofi announced an expansion of its global alliance with Regeneron to develop multiple next-generation, long-acting immunology antibodies.
View full filing details →Sanofi announced a strategic partnership with Cheplapharm in mature medicines.
View full filing details →Has SNY ever done a stock split?
No stock splits are recorded for SNY.
Get Real-Time SNY Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free